MADISON – Governor Jim Doyle announced today that the Stratatech Corporation will receive a $750,000 award to help develop new techniques to use genetically-enhanced human skin substitutes that can heal wounds. Department of Administration Secretary Michael Morgan presented the award on behalf of the Governor today.
“Stratatech has the potential to achieve incredible breakthroughs that could save lives,” Governor Doyle said. “Biotechnology is a competitive industry and Wisconsin still has a lead, but we need to continue to support these efforts in a significant way at the state level.”
Established in 2000, Stratatech Corporation is a regenerative medicine company focused on the development of cell-based, tissue-engineered products for wound care. Stratatech is currently developing products that have been genetically enhanced to express natural, human wound-healing factors that reduce infection, improve blood flow to the wound, and increase the rate of healing with reduced scarring.
“The development of cell-based therapies for the treatment of acute and chronic wounds is important for Wisconsin citizens and the state’s biotechnology community,” said President, Dr. Lynn Allen-Hoffmann. “I’d like to thank the Department of Commerce for the funds to assist us with our work toward FDA approval and commercialization of StrataGraft tissue, the first in our pipeline of wound therapy products.”
The grant is from the Technology Development Fund (TDF) program within the Department of Commerce (Commerce). For more information on Commerce programs and services, contact the Commerce area development manager at www.commerce.wi.gov/BD/BD-Fax-0901.html.
